

U. PORTO

FMUP FACULDADE DE MEDICINA
UNIVERSIDADE DO PORTO

MESTRADO INTEGRADO EM MEDICINA

2018/2019

Diogo Miguel Fernandes da Rocha

**Which environment determinants
could explain Nontuberculous
Mycobacteria geographic incidence?**

Que fatores ambientais conseguem
explicar a incidência geográfica das
Micobactérias não tuberculosas?

março, 2019

FMUP

U. PORTO

FMUP FACULDADE DE MEDICINA
UNIVERSIDADE DO PORTO

Diogo Miguel Fernandes da Rocha

**Which environment determinants
could explain Nontuberculous
Mycobacteria geographic incidence?**

Que fatores ambientais conseguem
explicar a distribuição geográfica das
Micobactérias não tuberculosas?

Mestrado Integrado em Medicina

Área: Ciências médicas e da Saúde

Tipologia: Dissertação

**Trabalho efetuado sob a Orientação de:
Doutor Óscar António Louro Felgueiras**

Trabalho organizado de acordo com as normas da revista:

Pulmonology

março, 2019

FMUP

Eu, Diego Miguel Fernandes da Rocha, abaixo assinado, nº mecanográfico 201303683, estudante do 6º ano do Ciclo de Estudos Integrado em Medicina, na Faculdade de Medicina da Universidade do Porto, declaro ter atuado com absoluta integridade na elaboração deste projeto de opção.

Neste sentido, confirmo que **NÃO** incorri em plágio (ato pelo qual um indivíduo, mesmo por omissão, assume a autoria de um determinado trabalho intelectual, ou partes dele). Mais declaro que todas as frases que retirei de trabalhos anteriores pertencentes a outros autores, foram referenciadas, ou redigidas com novas palavras, tendo colocado, neste caso, a citação da fonte bibliográfica.

Faculdade de Medicina da Universidade do Porto, 15 / 03 / 2019

Assinatura conforme cartão de identificação:

Diego Miguel Fernandes da Rocha

NOME

Diego Miguel Fernandes da Rocha

NÚMERO DE ESTUDANTE

201303683

E-MAIL

up201303683@mat.up.pt

DESIGNAÇÃO DA ÁREA DO PROJECTO

Ciências médicas e da Saúde, Ciências da Saúde

TÍTULO DISSERTAÇÃO/~~MONOGRAFIA~~ (riscar o que não interessa)

Which environment determinants could explain Nontuberculous Mycobacteria geographic incidence?

ORIENTADOR

Dr. Oscar António Louro Felgueiras

COORIENTADOR (se aplicável)

ASSINALE APENAS UMA DAS OPÇÕES:

É AUTORIZADA A REPRODUÇÃO INTEGRAL DESTA TRABALHO APENAS PARA EFEITOS DE INVESTIGAÇÃO, MEDIANTE DECLARAÇÃO ESCRITA DO INTERESSADO, QUE A TAL SE COMPROMETE.	<input type="checkbox"/>
É AUTORIZADA A REPRODUÇÃO PARCIAL DESTA TRABALHO (INDICAR, CASO TAL SEJA NECESSÁRIO, Nº MÁXIMO DE PÁGINAS, ILUSTRAÇÕES, GRÁFICOS, ETC.) APENAS PARA EFEITOS DE INVESTIGAÇÃO, MEDIANTE DECLARAÇÃO ESCRITA DO INTERESSADO, QUE A TAL SE COMPROMETE.	<input type="checkbox"/>
DE ACORDO COM A LEGISLAÇÃO EM VIGOR, (INDICAR, CASO TAL SEJA NECESSÁRIO, Nº MÁXIMO DE PÁGINAS, ILUSTRAÇÕES, GRÁFICOS, ETC.) NÃO É PERMITIDA A REPRODUÇÃO DE QUALQUER PARTE DESTA TRABALHO.	<input checked="" type="checkbox"/>

Faculdade de Medicina da Universidade do Porto, 15/03/2019

Assinatura conforme cartão de identificação: Diego Miguel Fernandes da Rocha

Ao fim de dois anos
Dedico esta tese a mim
A todos os que me apoiaram
E àqueles que para ela contribuíram

DR

Which environment determinants could explain Nontuberculous Mycobacteria geographic incidence?

Diogo Rocha ^{a, *}, Óscar Felgueiras ^b, Raquel Duarte ^{c, d, e}

^a Faculdade de Medicina, Universidade do Porto, Portugal

^b Departamento de Matemática, Faculdade de Ciências, Universidade do Porto, Porto, Portugal

^c Departamento de Ciências da Saúde Pública e Forenses e Educação Médica, Faculdade de Medicina, Universidade do Porto, Porto, Portugal

^d ISPUP-EPIUnit, Faculdade de Medicina, Universidade do Porto, Porto, Portugal

^e Centro Hospitalar de Vila Nova de Gaia/Espinho

* Corresponding author, e-mail address: diogo7.rocha@gmail.com

Abstract

Introduction and Objectives: Nontuberculous mycobacteria (NTM) are opportunistic agents that have gained importance during the last decades due to their increasing incidence in high-risk populations. Their modes of transmission differ from person-to-person contact commonly described in *Mycobacterium tuberculosis* (MTB). In fact, NTM are frequently found in soil, natural waters and drinking-water distributions systems, emphasizing the contribution of environmental factors when discussing this disease's susceptibility. Our aim is to identify which environmental determinants could explain NTM geographic incidence in Portugal.

Material and Methods: We performed a transversal study centred on 2011 (date of the latest Portuguese census) from collected personal features and environmental data available in public databases. Environmental values when only known at the district level were interpolated using inverse distance weighting. A semiparametric poisson model was used to estimate NTM incidence. The non-parametric part of the model was obtained by using thin plate smoothing splines defined on the spatial component of the data.

Results: None of the environmental determinants studied was strong enough to predict NTM geographical incidence in Portugal ($p > 0.05$), except for population density ($p < 0.001$). Personal characteristics such as female sex ($p < 0.001$), age ($p < 0.001$) and Human Immunodeficiency Virus infection and Acquired Immune Deficiency Syndrome (HIV/AIDS) incidence ($p < 0.001$) are associated with an increase of NTM disease incidence.

Conclusions: NTM appears to be more common in elderly women, especially if they have HIV/AIDS disease or if they live in urban, highly populated areas. Overall, female sex seems to assume the most relevant role when discussing predisposition to NTM disease. However, further studies are needed to evaluate the impact on NTM geographical incidence by other environmental and personal variables not included in this one.

Keywords: Nontuberculous mycobacteria, environmental determinant, geographic distribution, Portugal

Introduction

Nontuberculous mycobacteria (NTM) are opportunistic human pathogens known to be an important cause of morbidity and mortality in immunocompromised individuals.¹ NTM epidemics have changed since the emergence of Human Immunodeficiency Virus infection and Acquired Immune Deficiency Syndrome (HIV/AIDS), transforming this rare infection into a common diagnosis in high-risk populations.²⁻⁴ Despite still being underdiagnosed, NTM prevalence has exponentially grown during the last decades and it will continue to increase given the larger life expectancy and the lengthened survival of risk groups in developed countries.^{1, 5, 6}

It is now known whether NTM are transmitted via aerosols.^{2, 4-6} A greater influencer in NTM epidemiology is its lipid-rich outer membrane constituted by long chain mycolic acids which confers them bigger impermeability and a slow growth rate.^{6, 7} This membrane's characteristics explain not only its preferential attachment to surfaces but also why NTM are so widespread despite its low rate division and impenetrability to hydrophobic nutrients.^{2, 5, 6, 8}

Originally, NTM were identified on natural waters and soils and unusual places such as acid, brown water swamps, boreal and peat rich soils and metal working fluids.^{2, 6} These findings show that NTM are able to thrive on a diverse range of organic compounds but mostly acidic waters and soils and areas with air:water interfaces; they also prove that its growth is not influenced by temperature range, salinity's degree or oxygen tension.^{2, 6, 8, 9} In addition to their presence in natural environments, NTM are frequently isolated from household plumbings, drinking-water distribution systems and hospital water systems where they proliferate as a biofilm which contributes to their intrinsic resistance to pollutants and heavy metals.^{2, 5-8} Also, human activities such as disinfection, promotion of polluted environments and injudicious use of antibiotics help to select bacteria progressively more resistant and accustomed to human environments, specially urban areas and most densely populated places.^{2, 6, 8}

Worldwide, NTM appear to be more frequent in tropical and subtropical regions; however, it is now recognized that epidemiological data varies according to geographical areas which in turn correlates with local clinical settings.^{8, 10} So, it is required to conduct epidemiological surveillance in order to provide local epidemiological data that is useful in the management of patients.¹⁰ In this study, we will study some environmental determinants (temperature, soil pH, humidity and precipitation) and its association with NTM geographic incidence in a nationwide basis.

Material and Methods

We conducted a transversal study centred on 2011 (date of the latest nationwide census performed in Portugal).

The new NTM cases reported between 2009 to 2013 were extracted from Sistema de Vigilância Intrínseco do Programa Nacional de Luta Contra a Tuberculose (SVIG-TB)¹¹, a public health surveillance system for tuberculosis cases in Portugal. Population density data and personal features of the Portuguese population such as age, sex, HIV/AIDS incidence and migrants' proportion were collected from the 2011 nationwide census organized by Instituto Nacional de Estatística (INE)¹², an institute responsible for producing official statistical data for the Portuguese government. Environmental determinants such as temperature, humidity and precipitation in the period between 2009 and 2013 were obtained from Instituto Português do Mar e da Atmosfera (IPMA)¹³, a public institute with nationwide research responsibilities concerning the ocean and the atmosphere. Soil pH data were collected from the European Soil Data Centre (ESDAC) dataset^{14, 15}, a project from the Joint Research Centre (JRC) organised by the European Commission¹⁶. To simplify our geographical analyses, we excluded Azores and Madeira's archipelagos and considered the 278 portuguese municipalities as the spatial reference units. All data were collected according to this geographical division, except for IPMA's data which were only available for districts.

Microsoft EXCEL (2013) and R (version 3.5.2) were the data analyses tools used. Values collected from IPMA are monthly averages over a 5-year period and were interpolated using the inverse distance weighting method in order to obtain values for each municipality. Semiparametric poisson models were used to estimate NTM incidence. The non-parametric part of the models was obtained by using thin plate smoothing splines defined on the spatial component of the data. All models include the spatial component so that each explanatory variable is adjusted for geographical localization. Selection of variables in order to obtain a final model was made using the backward stepwise method. The level of significance was set at a $p < 0.05$.

Results

Between 2009 and 2013, 359 new NTM cases were reported to SVIG-TB (mean=71.8 cases/year). The majority came from Lisbon and Oporto regions, the most populated areas in Portugal.

As for the environmental variables, we found a positive effect of population density on the NTM geographical incidence (Expected effect (EE) = 1.123, CI = 1.054-1.198). Humidity (EE = 1.21, CI = 0.802-1.825) and precipitation (EE = 1.044, CI = 0.964-1.130) had the same effect but in a smaller magnitude. Conversely, mean temperate (EE = 0.399, CI = 0.077-2.076) and pH (EE = 0.859, CI = 0.575-1.283) were associated with a negative effect on NTM geographical incidence. Except for population density, none of those associations were statistically significant ($p > 0.05$). (Table 1)

Regarding personal features, sex has shown to have the greatest effect on NTM geographical incidence (EE = 0.695, CI = 0.612-0.788), being that male sex appears to act

as a protective factor on NTM infection. Age older than 45 years old had the second greater effect on NTM geographical incidence (EE = 1.091, CI = 1.049-1.134). HIV/AIDS incidence (EE = 1.019, CI = 1.010-1.028) was also positively associated to NTM geographical incidence. The migrants' proportion was another variable positively related to NTM geographical incidence but not as strong as others (EE = 1.095, CI = 1.029-1.164). (Table 2)

Discussion

We studied all patients notified with NTM in a period of 5 years (n=359). We could find some effect of environmental determinants on NTM geographical incidence although without statistical significance, exception made for population density. Personal characteristics such as female sex (p<0.001), age (p<0.001) and HIV/AIDS incidence (p<0.001) demonstrated a positive effect on the NTM geographical incidence.

Cassidy et al. described the microbiologic and demographic features of NTM disease when estimating the population-based prevalence of pulmonary and extrapulmonary NTM cases in Oregon. They were capable of associating the higher prevalence of disease in western, more urban portion of Oregon to a wetter and more temperate climate relatively to what was observed in rural areas of the same state.¹ In a study conducted by *Livanainen et al.* to evaluate the impact of environmental factors on the occurrence of environmental mycobacteria, they found that the number of total NTM in Finnish brook waters also correlated positively with precipitation.^{2, 17} They proved that in rainy periods there is an increase in chemical oxygen demand, acidity and counts of mycobacteria in the waters.¹⁷

In our population we also found a positive effect of humidity and precipitation and a negative one by pH and temperature on NTM geographical incidence, albeit not being statically significant. In part, these results can be explained by our small sample size.

We found as well that the population density positively influences NTM incidence. *Cassidy et al.* also confirmed this when they studied NTM cases in Oregon residents.¹ They found a higher prevalence of disease in western, more urban portion of Oregon that they attributed to the use of municipal water systems, since it had already been demonstrated in urban communities of Boston in 1970s / 80s that water stored in reservoirs for long periods of time promotes biofilm formation.^{1, 18, 19} However, likewise *Cassidy et al.* admitted, it is possible that these results are influenced by a diagnostic bias since patients with chronic lung diseases might more commonly live in urban areas and therefore more easily seek medical care.¹

'Windermere syndrome' corresponds to a single case of an elderly, non-smoking, thin woman where pulmonary disease was for the first time attributed to NTM.^{1, 5, 20}

Subsequent studies confirmed that NTM pulmonary disease is more common in previous healthy elderly women.^{7, 9, 10, 19, 21-23} This is similar with our findings that female sex and

age greater than 45 years old are, respectively, the first and second best NTM geographical incidence's influencers when analysed individually. But when creating a model starting with all significant variables together with geographic variation and applying a selection of variables procedure, sex is the only one to appear in the final model (see Figure 1 and Figure 2). Although *Stout et al.* confirmed this increase in NTM incidence with age, they argued that gender predominance in NTM could be wrongly overestimated in men by the different prevalence of smoking-associated lung damage between males and females.^{5, 9}

Our study similarly found a positive influence of HIV/AIDS incidence on NTM geographical incidence. This is in accordance with the current evidence that NTM cases are highest among immunosuppressed groups.^{1, 3-5, 24} Considering the Portuguese landscape, the relationship between HIV/AIDS incidence and NTM geographical incidence was strongest in Lisbon and Oporto regions, areas where HIV/AIDS incidence is higher.²⁵

Finally, our study still found that migrants' proportion has a small effect on NTM geographical incidence. A plausible theory is that migrants usually live in suburban and urban areas of the country's most populated cities but with worse accesses to health care facilities and diminished hygienic-sanitary conditions when compared to the country's natives.^{1, 2, 6, 26, 27} However, the idea that NTM disease is more common in the migrant population has been debated in more recent works. In a study carried out in Canada by *Hernandez-Garduno et al.* to determine the risk factors for pulmonary colonization by NTM, they concluded that NTM colonization risk is not so different between Canadian-born people and foreign-born people residing in Canada for at least 10 years.²⁸ This underlines the cumulative risk of exposure to environmental sources.

Other authors have already identified others personal features as risk factors to NTM disease. Commonly, NTM infection is greater in individuals with prior or current lung diseases, patients exposed to the aspiration of gastric contents, individuals with deformations of the chest or individuals immunosuppressed by others motifs than HIV/AIDS.^{4, 5, 9, 10, 29, 30} Genetic causes were also implicated in the pathophysiology of NTM infection.^{5, 7} For example, *Kotilainen et al.* proposed C4 deficiency as a risk factor to NTM pulmonary infection in elderly female patients.⁷ Other works identified defects in the interleukin-12/interferon-gamma axis in families predisposed to rare disseminated NTM disease.^{5, 7, 30-32} Although the available evidence is limited, there is some suggestion that tobacco and alcohol may be cofactors in the development of NTM pulmonary involvement.⁴⁻⁶ Lastly, race appears to play a part in NTM disease susceptibility.^{19, 28} In their works, *Bodle et al.* identified a higher prevalence of NTM positive cultures in white persons from a sample of patients in New York City.¹⁹ Given the large number of personal features highlighted here, it is not surprising that those were the most promising factors in our study.

The strength of this study is that it is a nationwide longitudinal study with NTM cases routinely notified by family physicians. One of the limitations associated is related to the

few environmental variables analysed. This was limited by the scarce data collected by the meteorological stations that are property of IPMA. Another limitation is the fact that our study used data from 2011, so it could be argued that the conclusions found are valid only for that period and no further. Also, the small number of NTM cases identified per year made it more difficult to find any statically significant result between environmental determinants and NTM incidence. Moreover, local differences in health services assessment and inequality expertise in NTM diagnosis by regional hospitals could have negatively influenced the relations studied.^{5, 9, 29} Additionally, the mathematical approach applied to the IPMA data to derive values from districts to municipalities could similarly influence the results encountered. So, a more judicious study design should be implanted in future researches to minimize these glitches.

Conclusion

Although we had found some correlations between environmental determinants and NTM geographical incidence in Portugal's mainland, most of them did not turn out to be statistically significant. However, personal variables such as sex, age and HIV/AIDS incidence revealed to have a greater effect on this outcome. Further studies are needed with a larger sample and with inclusion of other environmental determinants not routinely measured.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial or non-profit sectors.

Conflicts of interest

The authors have no conflicts of interest to declare.

Acknowledgements

The authors would like to thank ISPUP (Instituto de Saúde Pública da Universidade do Porto) for helping collect all data from SVIG-TB and ESDAC datasets and, importantly, for making a financial effort to acquire meteorological data from IPMA.

References

1. Cassidy, P.M., et al., *Nontuberculous mycobacterial disease prevalence and risk factors: a changing epidemiology*. Clin Infect Dis, 2009. **49**(12): p. e124-9.
2. Falkinham, J.O., 3rd, *Epidemiology of infection by nontuberculous mycobacteria*. Clin Microbiol Rev, 1996. **9**(2): p. 177-215.
3. Kim, C.H., et al., *Comparison of the incidence between tuberculosis and nontuberculous mycobacterial disease after gastrectomy*. Infection, 2014. **42**(4): p. 697-704.
4. Wilinska, E., et al., *Non-tuberculous mycobacterial lung disease (NT MLD) in patients with chronic thromboembolic pulmonary hypertension and idiopathic pulmonary arterial hypertension*. Pneumonol Alergol Pol, 2014. **82**(6): p. 495-502.
5. Stout, J.E., W.J. Koh, and W.W. Yew, *Update on pulmonary disease due to non-tuberculous mycobacteria*. Int J Infect Dis, 2016. **45**: p. 123-34.
6. Falkinham, J.O., 3rd, *Surrounded by mycobacteria: nontuberculous mycobacteria in the human environment*. J Appl Microbiol, 2009. **107**(2): p. 356-67.
7. Kotilainen, H., et al., *Complement C4 deficiency--a plausible risk factor for non-tuberculous mycobacteria (NTM) infection in apparently immunocompetent patients*. PLoS One, 2014. **9**(3): p. e91450.
8. Kothavade, R.J., et al., *Clinical and laboratory aspects of the diagnosis and management of cutaneous and subcutaneous infections caused by rapidly growing mycobacteria*. Eur J Clin Microbiol Infect Dis, 2013. **32**(2): p. 161-88.
9. Prevots, D.R. and T.K. Marras, *Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review*. Clin Chest Med, 2015. **36**(1): p. 13-34.
10. Mertaniasih, N.M., et al., *Nontuberculous mycobacterial species and Mycobacterium tuberculosis complex coinfection in patients with pulmonary tuberculosis in Dr. Soetomo Hospital, Surabaya, Indonesia*. Int J Mycobacteriol, 2017. **6**(1): p. 9-13.
11. Direção-Geral da Saúde. *SVIG-TB*. 2019 [cited 2019 29 Jan]; Available from: <https://www.dgs.pt/paginas-de-sistema/saude-de-a-a-z/tuberculose1/sistema-svig-tb.aspx>.
12. Instituto Nacional de Estatística. *Censos 2011*. 2018 [cited 2018 04 Mar]; Available from: <https://censos.ine.pt/xportal/xmain?xpid=CENSOS&xpgid=censos-homepage>.
13. Instituto Português do Mar e da Atmosfera. *Dados meteorológicos*. 2018 [cited 2018 5 Mar]; Available from: <http://www.ipma.pt/pt/index.html/>.
14. Panagos, P., et al., *European Soil Data Centre: Response to European policy support and public data requirements*. Land Use Policy, 2012. **29**(2): p. 329-338.
15. Reuter, H., et al., *Continental-scale digital Soil Mapping using European Soil Profile Data: Soil pH*. Vol. 19. 2008. 91-102.
16. European Commission, J.R.C. *Map of Soil pH in Europe*. 2010 [cited 2017 17 Out]; Available from: <http://esdac.jrc.ec.europa.eu>.
17. Iivanainen, E.K., et al., *Environmental factors affecting the occurrence of mycobacteria in brook waters*. Appl Environ Microbiol, 1993. **59**(2): p. 398-404.
18. du Moulin, G.C., et al., *Mycobacterium avium complex, an emerging pathogen in Massachusetts*. J Clin Microbiol, 1985. **22**(1): p. 9-12.
19. Bodle, E.E., et al., *Epidemiology of Nontuberculous Mycobacteria in Patients without HIV Infection, New York City*. Emerging Infectious Diseases, 2008. **14**(3): p. 390-396.
20. Reich, J.M. and R.E. Johnson, *Mycobacterium avium complex pulmonary disease presenting as an isolated lingular or middle lobe pattern. The Lady Windermere syndrome*. Chest, 1992. **101**(6): p. 1605-9.
21. Yeh, J.J., et al., *Nontuberculosis mycobacterium disease is a risk factor for chronic obstructive pulmonary disease: a nationwide cohort study*. Lung, 2014. **192**(3): p. 403-11.
22. Kim, H.S., et al., *Serial CT findings of Mycobacterium massiliense pulmonary disease compared with Mycobacterium abscessus disease after treatment with antibiotic therapy*. Radiology, 2012. **263**(1): p. 260-70.

23. Park, Y.S., et al., *Rapid increase of non-tuberculous mycobacterial lung diseases at a tertiary referral hospital in South Korea*. Int J Tuberc Lung Dis, 2010. **14**(8): p. 1069-71.
24. Durao, V., et al., *Portuguese in vitro antibiotic susceptibilities favor current nontuberculous mycobacteria treatment guidelines*. Pulmonology, 2018.
25. Departamento de Doenças Infeciosas, I.N.d.S.D.R.J., *Infeção VIH e SIDA: a situação em Portugal a 31 de dezembro de 2017*. 2018.
26. Fernandez-Nino, J.A., et al., *Lifestyles and health status of migrants in a settlement of Barranquilla, Colombia, 2018*. Rev Salud Publica (Bogota), 2018. **20**(4): p. 530-538.
27. Jacobson, M.L., et al., *Tuberculosis risk among migrant farm workers on the Delmarva peninsula*. Am J Public Health, 1987. **77**(1): p. 29-32.
28. Hernandez-Garduno, E. and R.K. Elwood, *Demographic risk factors of pulmonary colonization by non-tuberculous mycobacteria*. Int J Tuberc Lung Dis, 2010. **14**(1): p. 106-12.
29. Liao, T.L., et al., *Risk Factors and Outcomes of Nontuberculous Mycobacterial Disease among Rheumatoid Arthritis Patients: A Case-Control study in a TB Endemic Area*. Sci Rep, 2016. **6**: p. 29443.
30. Kuroda, F., et al., *Nontuberculous mycobacterium diseases and chronic thromboembolic pulmonary hypertension*. Intern Med, 2014. **53**(20): p. 2273-9.
31. Dorman, S.E. and S.M. Holland, *Interferon-gamma and interleukin-12 pathway defects and human disease*. Cytokine Growth Factor Rev, 2000. **11**(4): p. 321-33.
32. Fernando, S.L. and W.J. Britton, *Genetic susceptibility to mycobacterial disease in humans*. Immunol Cell Biol, 2006. **84**(2): p. 125-37.

Anexos



Pulmonology

AUTHORS INFORMATION PACK

GUIDE FOR AUTHORS

INTRODUCTION

Pulmonology (previously *Revista Portuguesa de Pneumologia*) will consider for publication papers (original articles or revisions, case reports, letters to the editor, commentaries etc) that are related directly or indirectly with the Respiratory System. The opinions expressed are exclusively the responsibility of the authors.

Only manuscripts containing original material which has not yet been published, wholly or partially (including tables and figures), and which have not been submitted to be published elsewhere, will be considered for publication. Before submitting manuscripts, authors must obtain all necessary authorizations for the publication of the submitted material.

Texts should be written in English.

Types of article

Articles on original research: The text must not exceed 2500 words, excluding references and tables, and be organized into introduction, methods, results, discussion and conclusions, with a maximum of 4 tables and/or figures. In the materials and methods there must be a complete and appropriate reference to the statistical methods used and the results should be quite sufficiently explicit.

Review articles: *Pulmonology* publishes primarily review articles which have been requested by the editors. However, unsolicited articles submitted will be considered, particularly systematic reviews (meta-analysis). The text must not exceed 5000 words, excluding references and tables, with a maximum of 5 tables and/or figures in total. The reviews must be organized systematically in introduction, methods, results and discussion.

Short publications: Preliminary results or new findings could lead to short publications. The text should not exceed 1000 words, excluding references and tables, and be organized into introduction, methods, results and discussion, with a maximum of 2 tables and/or figures in total and up to 10 references. The short publications should be submitted with formal abstracts in English, of not more than 250 words.

Commentaries: Commentaries, essays, critical analyses or declarations of a position in relation to topics of interest in the area of health, particular the politics of health and medical education will be considered. The text must not exceed 900 words, excluding references and tables, and include a maximum of one table or figure. Commentaries do not require abstracts; they will normally be at the request of the editors.

Special articles: Where appropriate the editorial board may invite one or various authors to write an article on a subject of particular formative interest in achieving the priorities of the journal and where the subject matter is not being addressed by other areas of study (for example postgraduate study).

Clinical case studies (case reports): The text should not exceed 1200 words, excluding references and tables, with a maximum of 2 tables and/or figures in total. Clinical case studies

should be submitted with formal abstracts in English, of not more than 120 words. Depending on their interest and originality the clinical case studies may include a commentary/discussion by one of the editors or by an invited reviewer (**Clinical case study with discussion**).

Letters to the editor: Two types of letter to the editor are considered, clinical notes and correspondence.

Clinical notes stand for a very objective reporting of results of clinical observation or original research for which a detailed development is not appropriate. The text should not exceed 800 words, excluding references and tables, and can include a maximum of two tables or figures and up to 7 references.

Correspondence refers to a succinct commentaries on articles published in the Portuguese Journal of Pulmonology, preferably within the previous 6 months. In this case, the text should not exceed 500 words, excluding references and tables, and can include a maximum of one table or figure and up to 5 references.

Letters to the editor should not include abstracts.

In manuscripts signed by more than 6 authors (3 authors in the case of letters to the editor), there has to be an explicit explanation for such an extensive authorship.

Manuscripts submitted to *Pulmonology* must conform to the recommendations indicated here and must be accompanied by a covering letter. The Editorial Board will acknowledge receipt of manuscripts, supplying information as to the orientation category given to the relevant article. Whenever there are editorial recommendations to changes to the manuscripts sent, the authors should supply a new version with an explanation of changes made. Correspondence between the authors and the journal should be conducted electronically, by the Elsevier Editorial System (<http://ees.elsevier.com/pulmoe>).

Submission checklist

You can use this list to carry out a final check of your submission before you send it to the journal for review. Please check the relevant section in this Guide for Authors for more details.

Ensure that the following items are present:

One author has been designated as the corresponding author with contact details:

- E-mail address
- Full postal address

All necessary files have been uploaded:

Manuscript:

- Include keywords
- All figures (include relevant captions)
- All tables (including titles, description, footnotes)
- Ensure all figure and table citations in the text match the files provided
- Indicate clearly if color should be used for any figures in print

Graphical Abstracts / Highlights files (where applicable)

Supplemental files (where applicable)

Further considerations

- Manuscript has been 'spell checked' and 'grammar checked'
- All references mentioned in the Reference List are cited in the text, and vice versa
- **Permission has been obtained for use of copyrighted material from other sources (including the Internet)**
- A competing interests statement is provided, even if the authors have no competing interests to declare
- Journal policies detailed in this guide have been reviewed

- Referee suggestions and contact details provided, based on journal requirements

For further information, visit our [Support Center](#).

BEFORE YOU BEGIN

Ethics in publishing

Please see our information pages on [Ethics in publishing](#) and [Ethical guidelines for journal publication](#).

Human and animal rights

If the work involves the use of human subjects, the author should ensure that the work described has been carried out in accordance with [The Code of Ethics of the World Medical Association](#) (Declaration of Helsinki) for experiments involving humans. The manuscript should be in line with the [Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals](#) and aim for the inclusion of representative human populations (sex, age and ethnicity) as per those recommendations. The terms [sex and gender](#) should be used correctly.

Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.

All animal experiments should comply with the [ARRIVE guidelines](#) and should be carried out in accordance with the U.K. Animals (Scientific Procedures) Act, 1986 and associated guidelines, [EU Directive 2010/63/EU for animal experiments](#), or the National Institutes of Health guide for the care and use of Laboratory animals (NIH Publications No. 8023, revised 1978) and the authors should clearly indicate in the manuscript that such guidelines have been followed. The sex of animals must be indicated, and where appropriate, the influence (or association) of sex on the results of the study.

Declaration of interest

All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential competing interests include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding.

Authors must disclose any interests in two places: 1. A summary declaration of interest statement in the title page file (if double-blind) or the manuscript file (if single-blind). If there are no interests to declare then please state this: 'Declarations of interest: none'. This summary statement will be ultimately published if the article is accepted. 2. Detailed disclosures as part of a separate Declaration of Interest form, which forms part of the journal's official records. It is important for potential interests to be declared in both places and that the information matches. [More information](#).

Submission declaration and verification

Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis, see '[Multiple, redundant or concurrent publication](#)' section of our ethics policy for more information), that it is not under consideration for publication elsewhere, that its publication is approved by

all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify originality, your article may be checked by the originality detection service [Crossref Similarity Check](#).

Authorship

All authors should have made substantial contributions to all of the following: (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data, (2) drafting the article or revising it critically for important intellectual content, (3) final approval of the version to be submitted.

Changes to authorship

Authors are expected to consider carefully the list and order of authors **before** submitting their manuscript and provide the definitive list of authors at the time of the original submission. Any addition, deletion or rearrangement of author names in the authorship list should be made only **before** the manuscript has been accepted and only if approved by the journal Editor. To request such a change, the Editor must receive the following from the **corresponding author**: (a) the reason for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed.

Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of authors **after** the manuscript has been accepted. While the Editor considers the request, publication of the manuscript will be suspended. If the manuscript has already been published in an online issue, any requests approved by the Editor will result in a corrigendum.

Clinical trial results

In line with the position of the International Committee of Medical Journal Editors, the journal will not consider results posted in the same clinical trials registry in which primary registration resides to be prior publication if the results posted are presented in the form of a brief structured (less than 500 words) abstract or table. However, divulging results in other circumstances (e.g., investors' meetings) is discouraged and may jeopardise consideration of the manuscript. Authors should fully disclose all posting in registries of results of the same or closely related work.

Reporting clinical trials

Randomized controlled trials should be presented according to the CONSORT guidelines. At manuscript submission, authors must provide the CONSORT checklist accompanied by a flow diagram that illustrates the progress of patients through the trial, including recruitment, enrollment, randomization, withdrawal and completion, and a detailed description of the randomization procedure. The [CONSORT checklist and template flow diagram](#) are available online.

Registration of clinical trials

Registration in a public trials registry is a condition for publication of clinical trials in this journal in accordance with [International Committee of Medical Journal Editors](#) recommendations. Trials must register at or before the onset of patient enrolment. The clinical trial registration number should be included at the end of the abstract of the article. A clinical trial is defined as any research study that prospectively assigns human participants or groups of humans to one or

more health-related interventions to evaluate the effects of health outcomes. Health-related interventions include any intervention used to modify a biomedical or health-related outcome (for example drugs, surgical procedures, devices, behavioural treatments, dietary interventions, and process-of-care changes). Health outcomes include any biomedical or health-related measures obtained in patients or participants, including pharmacokinetic measures and adverse events. Purely observational studies (those in which the assignment of the medical intervention is not at the discretion of the investigator) will not require registration.

Copyright

Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (see [more information](#) on this). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.

Author rights

As an author you (or your employer or institution) have certain rights to reuse your work. [More information](#).

Elsevier supports responsible sharing

Find out how you can [share your research](#) published in Elsevier journals.

Role of the funding source

You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated.

If no funding has been provided for the research, please include the following sentence:

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Funding body agreements and policies

Elsevier has established a number of agreements with funding bodies which allow authors to comply with their funder's open access policies. Some funding bodies will reimburse the author for the Open Access Publication Fee. Details of [existing agreements](#) are available online.

Open access

This is an open access journal: all articles will be immediately and permanently free for everyone to read and download. To provide open access, this journal has an open access fee (also known as an article publishing charge APC) which needs to be paid by the authors or on their behalf e.g. by their research funder or institution. Permitted third party (re)use is defined by the following [Creative Commons user licenses](#):

Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

For non-commercial purposes, lets others distribute and copy the article, and to include in a collective work (such as an anthology), as long as they credit the author(s) and provided they do not alter or modify the article.

No fee is payable by the author as publishing costs are covered by the society.

Elsevier Researcher Academy

[Researcher Academy](#) is a free e-learning platform designed to support early and mid-career researchers throughout their research journey. The "Learn" environment at Researcher Academy offers several interactive modules, webinars, downloadable guides and resources to guide you through the process of writing for research and going through peer review. Feel free to use these free resources to improve your submission and navigate the publication process with ease.

Language (usage and editing services)

Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the [English Language Editing service](#) available from Elsevier's WebShop.

Informed consent and patient details

Studies on patients or volunteers require ethics committee approval and informed consent, which should be documented in the paper. Appropriate consents, permissions and releases must be obtained where an author wishes to include case details or other personal information or images of patients and any other individuals in an Elsevier publication. Written consents must be retained by the author but copies should not be provided to the journal. Only if specifically requested by the journal in exceptional circumstances (for example if a legal issue arises) the author must provide copies of the consents or evidence that such consents have been obtained. For more information, please review the [Elsevier Policy on the Use of Images or Personal Information of Patients or other Individuals](#). Unless you have written permission from the patient (or, where applicable, the next of kin), the personal details of any patient included in any part of the article and in any supplementary materials (including all illustrations and videos) must be removed before submission.

Submission

Our online submission system guides you stepwise through the process of entering your article details and uploading your files. The system converts your article files to a single PDF file used in the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for final publication. All correspondence, including notification of the Editor's decision and requests for revision, is sent by e-mail.

Submit your article

Please submit your article via <http://ees.elsevier.com/pulmoe>

All manuscripts are evaluated by members of the editorial board of the journal and acceptance for publication of articles or original research, clinical reports or series of case studies which are accepted, are subject to a technical assessment by the editorial board. In this evaluation process articles may be:

- a) Accepted without alteration
- b) Accepted after suggested modifications have been agreed by the authors
- c) Refused

Modifications and revisions – In the case of articles being accepted subject to modifications, changes must be made by the author within fifteen days (for “minor” modifications) or 2

months (for “major” modifications). The proof reading will be the responsibility of the Editorial Board unless the authors indicate otherwise. In the latter case the changes must be made within the time limit set by the Editorial Board, to comply with.

PREPARATION

Peer review

This journal operates a single blind review process. All contributions will be initially assessed by the editor for suitability for the journal. Papers deemed suitable are then typically sent to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor's decision is final. [More information on types of peer review.](#)

Use of word processing software

It is important that the file be saved in the native format of the word processor used. The text should be in single-column format. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. In particular, do not use the word processor's options to justify text or to hyphenate words. However, do use bold face, italics, subscripts, superscripts etc. When preparing tables, if you are using a table grid, use only one grid for each individual table and not a grid for each row. If no grid is used, use tabs, not spaces, to align columns. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the [Guide to Publishing with Elsevier](#)). Note that source files of figures, tables and text graphics will be required whether or not you embed your figures in the text. See also the section on Electronic artwork.

To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.

Article structure

Subdivision - unnumbered sections

Divide your article into clearly defined sections. Each subsection is given a brief heading. Each heading should appear on its own separate line. Subsections should be used as much as possible when cross-referencing text: refer to the subsection by heading as opposed to simply 'the text'.

Introduction

State the objectives of the work and provide an adequate background, avoiding a detailed literature survey or a summary of the results.

Material and methods

Provide sufficient details to allow the work to be reproduced by an independent researcher. Methods that are already published should be summarized, and indicated by a reference. If quoting directly from a previously published method, use quotation marks and also cite the source. Any modifications to existing methods should also be described.

Results

Results should be clear and concise.

Discussion

This should explore the significance of the results of the work, not repeat them. A combined Results and Discussion section is often appropriate. Avoid extensive citations and discussion of published literature.

Conclusions

The main conclusions of the study may be presented in a short Conclusions section, which may stand alone or form a subsection of a Discussion or Results and Discussion section.

Appendices

If there is more than one appendix, they should be identified as A, B, etc. Formulae and equations in appendices should be given separate numbering: Eq. (A.1), Eq. (A.2), etc.; in a subsequent appendix, Eq. (B.1) and so on. Similarly for tables and figures: Table A.1; Fig. A.1, etc.

Essential title page information

- **Title.** Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.
- **Author names and affiliations.** Please clearly indicate the given name(s) and family name(s) of each author and check that all names are accurately spelled. You can add your name between parentheses in your own script behind the English transliteration. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.
- **Corresponding author.** Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. This responsibility includes answering any future queries about Methodology and Materials. **Ensure that the e-mail address is given and that contact details are kept up to date by the corresponding author.**
- **Present/permanent address.** If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

Abstract

A concise and factual abstract is required. The abstract should state briefly the purpose of the research, the principal results and major conclusions. An abstract is often presented separately from the article, so it must be able to stand alone. For this reason, References should be avoided, but if essential, then cite the author(s) and year(s). Also, non-standard or uncommon abbreviations should be avoided, but if essential they must be defined at their first mention in the abstract itself.

Structured abstract

A structured abstract, by means of appropriate headings, should provide the context or background for the research and should state its purpose, basic procedures (selection of study subjects or laboratory animals, observational and analytical methods), main findings (giving specific effect sizes and their statistical significance, if possible), and principal conclusions. It

should emphasize new and important aspects of the study or observations.

The headings will consist of: «Introduction and Objectives», «Patients or Materials and Methods», «Results» and «Conclusions».

Keywords

Immediately after the abstract, provide a maximum of 6 keywords, using British spelling and avoiding general and plural terms and multiple concepts (avoid, for example, 'and', 'of'). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.

Abbreviations

Define abbreviations that are not standard in this field in a footnote to be placed on the first page of the article. Such abbreviations that are unavoidable in the abstract must be defined at their first mention there, as well as in the footnote. Ensure consistency of abbreviations throughout the article.

Acknowledgements

Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).

Formatting of funding sources

List funding sources in this standard way to facilitate compliance to funder's requirements:

Funding: This work was supported by the National Institutes of Health [grant numbers xxxx, yyyy]; the Bill & Melinda Gates Foundation, Seattle, WA [grant number zzzz]; and the United States Institutes of Peace [grant number aaaa].

It is not necessary to include detailed descriptions on the program or type of grants and awards. When funding is from a block grant or other resources available to a university, college, or other research institution, submit the name of the institute or organization that provided the funding.

If no funding has been provided for the research, please include the following sentence:

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Units

Follow internationally accepted rules and conventions: use the international system of units (SI). If other units are mentioned, please give their equivalent in SI.

Math formulae

Please submit math equations as editable text and not as images. Present simple formulae in line with normal text where possible and use the solidus (/) instead of a horizontal line for small fractional terms, e.g., X/Y. In principle, variables are to be presented in italics. Powers of e are often more conveniently denoted by exp. Number consecutively any equations that have to be displayed separately from the text (if referred to explicitly in the text).

Embedded math equations

If you are submitting an article prepared with Microsoft Word containing embedded math equations then please read this [related support information](#).

Artwork

Image manipulation

Whilst it is accepted that authors sometimes need to manipulate images for clarity, manipulation for purposes of deception or fraud will be seen as scientific ethical abuse and will be dealt with accordingly. For graphical images, this journal is applying the following policy: no specific feature within an image may be enhanced, obscured, moved, removed, or introduced. Adjustments of brightness, contrast, or color balance are acceptable if and as long as they do not obscure or eliminate any information present in the original. Nonlinear adjustments (e.g. changes to gamma settings) must be disclosed in the figure legend.

Electronic artwork

General points

- Make sure you use uniform lettering and sizing of your original artwork.
- Embed the used fonts if the application provides that option.
- Aim to use the following fonts in your illustrations: Arial, Courier, Times New Roman, Symbol, or use fonts that look similar.
- Number the illustrations according to their sequence in the text.
- Use a logical naming convention for your artwork files.
- Provide captions to illustrations separately.
- Size the illustrations close to the desired dimensions of the published version.
- Submit each illustration as a separate file.

A detailed [guide on electronic artwork](#) is available.

You are urged to visit this site; some excerpts from the detailed information are given here.

Formats

If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, Excel) then please supply 'as is' in the native document format.

Regardless of the application used other than Microsoft Office, when your electronic artwork is finalized, please 'Save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):

EPS (or PDF): Vector drawings, embed all used fonts.

TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of 300 dpi.

TIFF (or JPEG): Bitmapped (pure black & white pixels) line drawings, keep to a minimum of 1000 dpi.

TIFF (or JPEG): Combinations bitmapped line/half-tone (color or grayscale), keep to a minimum of 500 dpi.

Please do not:

- Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these typically have a low number of pixels and limited set of colors;
- Supply files that are too low in resolution;
- Submit graphics that are disproportionately large for the content.

Color artwork

Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF) or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color online (e.g., ScienceDirect and other sites). [Further information on the preparation of electronic artwork](#).

Illustration services

[Elsevier's WebShop](#) offers Illustration Services to authors preparing to submit a manuscript but concerned about the quality of the images accompanying their article. Elsevier's expert illustrators can produce scientific, technical and medical-style images, as well as a full range of charts, tables and graphs. Image 'polishing' is also available, where our illustrators take your image(s) and improve them to a professional standard. Please visit the website to find out more.

Figure captions

Ensure that each illustration has a caption. Supply captions separately, not attached to the figure. A caption should comprise a brief title (**not** on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

Tables

Please submit tables as editable text and not as images. Tables can be placed either next to the relevant text in the article, or on separate page(s) at the end. Number tables consecutively in accordance with their appearance in the text and place any table notes below the table body. Be sparing in the use of tables and ensure that the data presented in them do not duplicate results described elsewhere in the article. Please avoid using vertical rules and shading in table cells.

References

Citation in text

Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.

Reference links

Increased discoverability of research and high quality peer review are ensured by online links to the sources cited. In order to allow us to create links to abstracting and indexing services, such as Scopus, CrossRef and PubMed, please ensure that data provided in the references are correct. Please note that incorrect surnames, journal/book titles, publication year and pagination may prevent link creation. When copying references, please be careful as they may already contain errors. Use of the DOI is highly encouraged.

A DOI is guaranteed never to change, so you can use it as a permanent link to any electronic

article. An example of a citation using DOI for an article not yet in an issue is: VanDecar J.C., Russo R.M., James D.E., Ambeh W.B., Franke M. (2003). Aseismic continuation of the Lesser Antilles slab beneath northeastern Venezuela. *Journal of Geophysical Research*, <https://doi.org/10.1029/2001JB000884>. Please note the format of such citations should be in the same style as all other references in the paper.

Web references

As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.

Data references

This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly identify it as a data reference. This identifier will not appear in your published article.

References in a special issue

Please ensure that the words 'this issue' are added to any references in the list (and any citations in the text) to other articles in the same Special Issue.

Reference style

Text: Indicate references by superscript numbers in the text. The actual authors can be referred to, but the reference number(s) must always be given.

List: Number the references in the list in the order in which they appear in the text.

Examples:

Reference to a journal publication:

1. Van der Geer J, Hanraads JA, Lupton RA. The art of writing a scientific article. *J Sci Commun* 2010;**163**:51-9. <https://doi.org/10.1016/j.Sc.2010.00372>.

Reference to a journal publication with an article number:

2. Van der Geer J, Hanraads JA, Lupton RA. The art of writing a scientific article. *Heliyon*. 2018;**19**:e00205. <https://doi.org/10.1016/j.heliyon.2018.e00205>.

Reference to a book:

3. Strunk Jr W, White EB. *The elements of style*. 4th ed. New York: Longman; 2000.

Reference to a chapter in an edited book:

4. Mettam GR, Adams LB. How to prepare an electronic version of your article. In: Jones BS, Smith RZ, editors. *Introduction to the electronic age*, New York: E-Publishing Inc; 2009, p. 281-304.

Reference to a website:

5. Cancer Research UK. Cancer statistics reports for the UK, <http://www.cancerresearchuk.org/aboutcancer/statistics/cancerstatsreport/>; 2003 [accessed 13 March 2003].

Reference to a dataset:

[dataset] 6. Oguro M, Imahiro S, Saito S, Nakashizuka T. Mortality data for Japanese oak wilt disease and surrounding forest compositions, Mendeley Data, v1; 2015. <https://doi.org/10.17632/xwj98nb39r.1>.

Note shortened form for last page number. e.g., 51-9, and that for more than 6 authors the first 6 should be listed followed by 'et al.' For further details you are referred to 'Uniform Requirements for Manuscripts submitted to Biomedical Journals' (J Am Med Assoc 1997;**277**:927-34)(see also [Samples of Formatted References](#)).

Journal abbreviations source

Journal names should be abbreviated according to the [List of Title Word Abbreviations](#).

Video

Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. In order to ensure that your video or animation material is directly usable, please provide the file in one of our recommended file formats with a preferred maximum size of 150 MB per file, 1 GB in total. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including [ScienceDirect](#). Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our [video instruction pages](#). Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.

Supplementary material

Supplementary material such as applications, images and sound clips, can be published with your article to enhance it. Submitted supplementary items are published exactly as they are received (Excel or PowerPoint files will appear as such online). Please submit your material together with the article and supply a concise, descriptive caption for each supplementary file. If you wish to make changes to supplementary material during any stage of the process, please make sure to provide an updated file. Do not annotate any corrections on a previous version. Please switch off the 'Track Changes' option in Microsoft Office files as these will appear in the published version.

RESEARCH DATA

This journal encourages and enables you to share data that supports your research publication where appropriate, and enables you to interlink the data with your published articles. Research data refers to the results of observations or experimentation that validate research findings. To facilitate reproducibility and data reuse, this journal also encourages you to share your software, code, models, algorithms, protocols, methods and other useful materials related to the project.

Below are a number of ways in which you can associate data with your article or make a statement about the availability of your data when submitting your manuscript. If you are sharing data in one of these ways, you are encouraged to cite the data in your manuscript and reference list. Please refer to the "References" section for more information about data citation. For more information on depositing, sharing and using research data and other relevant research materials, visit the [research data page](#).

Data linking

If you have made your research data available in a data repository, you can link your article directly to the dataset. Elsevier collaborates with a number of repositories to link articles on ScienceDirect with relevant repositories, giving readers access to underlying data that give them a better understanding of the research described.

There are different ways to link your datasets to your article. When available, you can directly link your dataset to your article by providing the relevant information in the submission system. For more information, visit the [database linking page](#).

For [supported data repositories](#) a repository banner will automatically appear next to your published article on ScienceDirect.

In addition, you can link to relevant data or entities through identifiers within the text of your manuscript, using the following format: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN).

Mendeley Data

This journal supports Mendeley Data, enabling you to deposit any research data (including raw and processed data, video, code, software, algorithms, protocols, and methods) associated with your manuscript in a free-to-use, open access repository. Before submitting your article, you can deposit the relevant datasets to Mendeley Data. Please include the DOI of the deposited dataset(s) in your main manuscript file. The datasets will be listed and directly accessible to readers next to your published article online.

For more information, visit the [Mendeley Data for journals page](#).

Data statement

To foster transparency, we encourage you to state the availability of your data in your submission. This may be a requirement of your funding body or institution. If your data is unavailable to access or unsuitable to post, you will have the opportunity to indicate why during the submission process, for example by stating that the research data is confidential. The statement will appear with your published article on ScienceDirect. For more information, visit the [Data Statement page](#).

AFTER ACCEPTANCE

Proofs

One set of page proofs (as PDF files) will be sent by e-mail to the corresponding author (if we do not have an e-mail address then paper proofs will be sent by post) or, a link will be provided in the e-mail so that authors can download the files themselves. Elsevier now provides authors with PDF proofs which can be annotated; for this you will need to [download the free Adobe Reader](#), version 9 (or higher). Instructions on how to annotate PDF files will accompany the proofs (also given online). The exact system requirements are given at the [Adobe site](#).

If you do not wish to use the PDF annotations function, you may list the corrections (including replies to the Query Form) and return them to Elsevier in an e-mail. Please list your corrections quoting line number. If, for any reason, this is not possible, then mark the corrections and any other comments (including replies to the Query Form) on a printout of your proof and scan the pages and return via e-mail. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article

as accepted for publication will only be considered at this stage with permission from the Editor. We will do everything possible to get your article published quickly and accurately. It is important to ensure that all corrections are sent back to us in one communication: please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

Offprints

The corresponding author will be notified and receive a link to the published version of the open access article on [ScienceDirect](#). This link is in the form of an article DOI link which can be shared via email and social networks. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. Both corresponding and co-authors may order offprints at any time via Elsevier's [Webshop](#). Authors requiring printed copies of multiple articles may use Elsevier Webshop's 'Create Your Own Book' service to collate multiple articles within a single cover.

AUTHOR INQUIRIES

Visit the [Elsevier Support Center](#) to find the answers you need. Here you will find everything from Frequently Asked Questions to ways to get in touch.

You can also [check the status of your submitted article](#) or find out [when your accepted article will be published](#).

Apêndices

Table 1 Effect of each environmental variable adjusted to NTM geographic distribution

<u>Environmental determinants</u>	Expected effect (EE)	Confidence Interval [95% CI]	p value
Humidity (%)	1.210	0.802 - 1.825	0.363
Mean temperature (°C)	0.399	0.077 - 2.076	0.275
pH	0.859	0.575 - 1.283	0.457
Population density (thousands / km ²)	1.123	1.054 - 1.198	<0.001
Precipitation (mm or kg/m ²)	1.044	0.964 - 1.130	0.288

The value of expected effect translates how much more effect that variable will have on NTM geographical incidence. For example, considering humidity, for each increase of one percent in humidity there will be a 21% increase in expected NTM incidence. However, this increase does not inform us of the impact of this variable on NTM geographical incidence. For that, we must analyse the confidence interval since narrower and farthest intervals of 1 translate into a greater overall impact on NTM incidence.

Note: For each environmental determinant was considered the mean values from period 2009 to 2013, except for population density and pH.

Table 2 Effect of each personal feature adjusted to NTM geographic distribution

<u>Personal features</u>	Expected effect (EE)	Confidence Interval [95% CI]	p value
Age > 45 years old	1.091	1.049 - 1.134	<0.001
HIV/AIDS incidence (per 100.000 hab)	1.019	1.010 - 1.028	<0.001
Male sex (%)	0.695	0.612 - 0.788	<0.001
Proportion of migrants (per 1000 hab)	1.095	1.029 - 1.164	0.004

The value of expected effect translates how much more effect that variable will have on NTM geographical incidence. For example, considering age older than 45 years, for an increase of a percentage point in the proportion of older people in the population there will be a 9.1% increase in expected NTM incidence. However, this increase does not inform us of the impact of this variable on NTM geographical incidence. For that, we must analyse the confidence interval since narrower and farthest intervals of 1 translate into a greater overall impact on NTM incidence.

Note: For each personal feature, values from the 2011 portuguese census were considered.




Figure 1 NTM incidence model using geographical distribution as a single influencer. This model does not represent actual NTM cases distribution, but it is rather predicted NTM incidence variation solely by geographical distribution. White areas represent places with predictably highest NTM incidences. Red areas represent places with predictably lowest NTM incidences. Green lines are log-scale level curves that compare predicted NTM local incidences to the mean value of NTM incidence considered for Portugal's mainland.

x = longitude, y = latitude




Figure 2 Effect of geographic distribution on NTM incidence when adjusted to male proportion. In this model, we subtract the impact of sex on NTM incidence, considering that male proportion is the same for all municipalities. By doing this, we can see how much more geographical variation influences NTM incidence (comparatively to what was already explained by sex). This model predicts better actual NTM cases distribution because it matches geographical variation with male proportion.

x = longitude, y = latitude

Agradecimentos

Agradeço à Prof. Dr. ^a Raquel Duarte por todas as aprendizagens e por sempre ser uma pessoa-modelo para todos aqueles que se encontram ao seu redor.

Agradeço ao Prof. Dr. ^o Óscar Felgueiras pelo empenho contínuo e por sempre compreender as minhas dúvidas e hesitações.

Agradeço aos meus pais, irmã e restante família pelo constante apoio e por sempre desculparem as minhas ausências.

Agradeço ainda a todos os meus amigos

(sois todos muito especiais, não consigo nomear ninguém, estarão sempre no meu coração).

E agradeço por fim aos meus restantes colegas, conhecidos e anónimos por sempre permitirem que tudo se conjugasse a meu favor.

Um obrigado imenso!!